trastuzumab and gemcitabine in pretreated her2 overexpressing metastatic breast cancer patients retrospective analysis of our series曲妥珠单抗和吉西他滨进行预处理her2 overexpressing转移性乳腺癌患者的回顾性分析.pdfVIP

Hindawi Publishing Corporation Journal of Oncology Volume 2012, Article ID 198412, 6 pages doi:10.1155/2012/198412 Clinical Study Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series Vincenzo Di Lauro,1 Elena Torrisi,1 Ettore Bidoli,2 Daniela Quitadamo,3 Sara Cecco,4 and Andrea Veronesi1 1 Division of Medical Oncology C, Centro di Riferimento Oncologico, 33081 Aviano, Italy 2 Epidemiology Unit, Centro di Riferimento Oncologico, 33081 Aviano, Italy 3 Clinical Trial Offi ce, Centro di Riferimento Oncologico, 33081 Aviano, Italy 4 Pharmacy Unit, Centro di Riferimento Oncologico, 33081, Aviano, Italy Correspondence should be addressed to Vincenzo Di Lauro, vdilauro@cro.it Received 26 October 2011; Revised 5 January 2012; Accepted 20 January 2012 Academic Editor: Bruno Vincenzi Copyright © 2012 Vincenzo Di Lauro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Trastuzumab-based regimes improved clinical outcome in women with overexpressing HER2 metastatic breast cancer, mainly due to the availability of different combination therapies, clinically active and well tolerated. In this study we retrospectively evaluated clinical activity and toxicity of trastuzuamb plus gemcitabine regimen in heavily pretreated HER2 positive metastatic breast cancer patients. Although the observed population was heavily pretreated, the evaluated regimen was notably effective in terms of response rate, time to progression and survival, with very mild toxicity. These data suggest that in over expressing HER2 metastatic breast c